Exploring the complex etiology of oncogenic fusions in childhood cancer (2019) Anderson ND, De Borja R, Young MD, Fuligni F, Rosic A, Roberts ND, Pillay N, et al. Conference contribution Analytical and inter-observer comparability of 4 clinically developed programmed death-ligand 1 (PD-L1) immunohistochemistry assays in advanced clear cell renal cell carcinoma (CCRCC) (2019) Sommer U, Eckstein M, Ammann J, Braunschweig T, Macher-Goeppinger S, Schwamborn K, Hieke-Schulz S, et al. Conference contribution Role of IFN-gamma-activation of distinct tumor and stromal cell populations in colorectal carcinoma pathogenesis (2019) Britzen-Laurent N, Guo W, Langer V, Khoziainova S, Weisenburger T, Winkler T, Straube J, et al. Conference contribution Strong expression of EZH2 and H3K27me3 is associated with poor survival time in small cell lung cancer (2019) Fernandes AP, Alves RDS, Watte G, Kunze P, Roehe AV, Schneider-Stock R Conference contribution Tumor budding: A predictor for metastasis in the CAM xenograft model (2019) Muenzner JK, Ranjan RA, Eckstein M, Erber R, Kunze P, Geppert CI, Rübner M, et al. Conference contribution Protein levels of Piwi-like 1 and-2 protein are prognostic factors for muscle invasive urothelial bladder cancer patients (2019) Eckstein M, Jung R, Weigelt K, Sikic D, Stöhr R, Geppert CI, Agaimy A, et al. Conference contribution Intratumoral RNA-based TLR-7/-8 and RIG-I agonist CV8102 alone and in combination with anti-PD-1 in a Phase I dose-escalation and expansion trial in patients with advanced solid tumors (2019) Eigentler T, Krauss J, Schreiber J, Weishaupt C, Terheyden P, Heinzerling L, Mohr P, et al. Conference contribution Clinical relevance of comprehensive genomic analysis in patients with advanced-stage neuroendocrine neoplasms: Results from the MASTER trial of the German Cancer Consortium (2019) Kreutzfeldt S, Apostolidis L, Oles M, Horak P, Heilig CE, Heining C, Hutter B, et al. Conference contribution Interleukin 6 transsignaling is a candidate mechanism to drive progression of human DCCs during periods of clinical latency (2019) -Klein MW, Grujovic A, Obradovic M, Hoffmann M, Lu X, Kirsch S, Treitschke S, et al. Conference contribution SPARCL1 is an angiocrine inhibitor of tumorigenesis in colorectal carcinoma (2019) Tenkerian C, Regensburger D, Langer V, Klingler A, Borau A, Sticht H, Ramming A, et al. Conference contribution